JP2013508452A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508452A5
JP2013508452A5 JP2012536664A JP2012536664A JP2013508452A5 JP 2013508452 A5 JP2013508452 A5 JP 2013508452A5 JP 2012536664 A JP2012536664 A JP 2012536664A JP 2012536664 A JP2012536664 A JP 2012536664A JP 2013508452 A5 JP2013508452 A5 JP 2013508452A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
hydroxy
heterocyclic ring
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012536664A
Other languages
English (en)
Japanese (ja)
Other versions
JP5820813B2 (ja
JP2013508452A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2010/007344 external-priority patent/WO2011052950A2/en
Publication of JP2013508452A publication Critical patent/JP2013508452A/ja
Publication of JP2013508452A5 publication Critical patent/JP2013508452A5/ja
Application granted granted Critical
Publication of JP5820813B2 publication Critical patent/JP5820813B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012536664A 2009-10-26 2010-10-25 インドール化合物を含む医薬組成物 Active JP5820813B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2009-0101978 2009-10-26
KR20090101978 2009-10-26
KR10-2010-0098511 2010-10-08
KR20100098511 2010-10-08
PCT/KR2010/007344 WO2011052950A2 (en) 2009-10-26 2010-10-25 Pharmaceutical composition comprising indole compound

Publications (3)

Publication Number Publication Date
JP2013508452A JP2013508452A (ja) 2013-03-07
JP2013508452A5 true JP2013508452A5 (enExample) 2015-04-30
JP5820813B2 JP5820813B2 (ja) 2015-11-24

Family

ID=43922791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012536664A Active JP5820813B2 (ja) 2009-10-26 2010-10-25 インドール化合物を含む医薬組成物

Country Status (12)

Country Link
US (2) US20120214804A1 (enExample)
EP (1) EP2493469A4 (enExample)
JP (1) JP5820813B2 (enExample)
KR (1) KR101325272B1 (enExample)
CN (1) CN102596198B (enExample)
AR (1) AR078775A1 (enExample)
BR (1) BR112012009894A2 (enExample)
MX (1) MX338807B (enExample)
RU (1) RU2557243C2 (enExample)
TR (1) TR201204895T1 (enExample)
TW (2) TWI535440B (enExample)
WO (1) WO2011052950A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101304772B1 (ko) * 2011-04-11 2013-09-05 인제대학교 산학협력단 NecroX―5를 유효성분으로 포함하는 미토콘드리아 기능 조절용 조성물
WO2013115457A1 (ko) * 2012-01-31 2013-08-08 인제대학교 산학협력단 NecroX를 함유하는 암 전이 억제용 조성물
KR101400346B1 (ko) * 2012-01-31 2014-05-30 인제대학교 산학협력단 NecroX를 함유하는 암 전이 억제용 조성물
CN106659722A (zh) * 2014-04-18 2017-05-10 株式会社Lg生命科学 用于预防或治疗脂肪肝疾病的组合物
KR102596106B1 (ko) 2014-06-30 2023-10-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 연령-관련 증상 및 질환의 치료를 위한 케토부티레이트 화합물 및 조성물
KR101633703B1 (ko) * 2014-12-30 2016-06-27 한국원자력의학원 necro X-5를 유효성분으로 포함하는 방사선 조사에 의한 세포손상 예방 또는 치료용 조성물
CN107434819B (zh) * 2017-02-15 2020-03-17 河北医科大学第二医院 吲哚-tempo缀合物及其在保护远隔器官对抗缺血再灌注损伤中的用途
JP7069295B2 (ja) 2017-08-17 2022-05-17 エックスダブリューファルマ リミテッド 活性酸素種スカベンジャー誘導体の調製および使用
CN111356699B (zh) 2017-09-04 2022-08-23 凯瑞康宁生物工程(武汉)有限公司 活性氧清除剂的制备及用途
WO2020117003A1 (ko) 2018-12-06 2020-06-11 국립암센터 Nc886을 포함하는 암살상 바이러스 활성 증진 또는 생산 증진용 조성물
US11795147B2 (en) 2019-08-26 2023-10-24 Boehringer Ingelheim International Gmbh Modulators of complex I
WO2022039506A1 (ko) 2020-08-19 2022-02-24 주식회사 미토이뮨테라퓨틱스 Mabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
CN117136185A (zh) 2021-04-12 2023-11-28 水疗免疫疗法有限公司 5-[(1,1-二氧化-4-硫代吗啉基)甲基]-2-苯基-n-(四氢-2h-吡喃-4-基)-1h-吲哚-7-胺的新晶型
KR20220141252A (ko) 2021-04-12 2022-10-19 주식회사 미토이뮨테라퓨틱스 5-[(1,1-디옥시도-4-티오몰포리닐)메틸]-2-페닐-n-(테트라하이드로-2h-피란-4-일)-1h-인돌-7-아민 황산염 및 이의 신규 결정형
WO2023182840A1 (ko) * 2022-03-25 2023-09-28 주식회사 미토이뮨테라퓨틱스 항바이러스용 약학적 조성물 및 이의 용도
DE102023204801A1 (de) * 2023-05-23 2024-11-28 Continental Reifen Deutschland Gmbh Verbindung als Alterungsschutzmittel in Kautschukmischungen und Fahrzeugreifen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6420429B1 (en) * 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
EP1020465B1 (en) * 1997-09-05 2008-01-23 Lead Chemical Co. Ltd. Stereoisomeric indole compounds, process for the preparation of the same, and use thereof
CA2352144A1 (en) 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds
IL130169A (en) * 1999-05-27 2006-08-20 Neurim Pharma 1991 Derivatives of indole, and pharmaceutical, skin-protective and cosmetic compositions containing them
AR039209A1 (es) * 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US20060160748A1 (en) * 2003-11-25 2006-07-20 Shey-Shing Sheu Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
AU2005231336A1 (en) * 2004-03-29 2005-10-20 Inotek Pharmaceuticals Corporation Pyridyl-Substituted Porphyrin Compounds and methods of use thereof
CA2568134A1 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
CA2606053A1 (en) 2005-04-21 2006-11-02 Glenn Goldstein N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
US20070161609A1 (en) 2006-01-10 2007-07-12 Charles Buck Use of mitochondrially targeted antioxidant in treatment and prevention of drug-induced liver disease
EP2178870B1 (en) * 2007-08-17 2018-09-19 LG Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
RU2450001C2 (ru) 2007-12-20 2012-05-10 Эл Джи Лайф Сайенсиз Лтд. Активаторы глюкокиназы и фармацевтические композиции, содержащие их в качестве активного ингредиента
KR101098583B1 (ko) 2008-01-04 2011-12-26 주식회사 엘지생명과학 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체

Similar Documents

Publication Publication Date Title
JP2009538897A5 (enExample)
JP2021534124A5 (enExample)
JP2016517417A5 (enExample)
JP2014521653A5 (enExample)
JP2013508279A5 (enExample)
JP2013537203A5 (enExample)
JP2016516043A5 (enExample)
JP2009535307A5 (enExample)
JP2011504903A5 (enExample)
RU2011149256A (ru) Пестицидные композиции
JP2015504067A5 (enExample)
RU2013119129A (ru) Органические соединения
JP2014525420A5 (enExample)
JP2009542716A5 (enExample)
RU2015121037A (ru) Производные фенилэтилпиридина в качестве ингибиторов pde-4
JP2011526917A5 (enExample)
JP2013531029A5 (enExample)
JP2014521701A5 (enExample)
JP2014508804A5 (enExample)
JP2011509309A5 (enExample)
RU2014146995A (ru) Сульфонамидное производное и его медицинское применение
JP2010513322A5 (enExample)
JP2015504081A5 (enExample)
JP2015522650A5 (enExample)
JP2014513727A5 (enExample)